Protein tyrosine phosphatase receptor type D (PTPRD) is a tumor suppressor gene that is epigenetically silenced and mutated in several cancers, including breast cancer. Since IL-6/STAT3 signaling is often hyperactivated in breast cancer and STAT3 is a direct PTPRD substrate, we investigated the role of PTPRD in breast cancer and the association between PTPRD and IL-6/STAT3 signaling. We found that PTPRD acts as a tumor suppressor in breast cancer tissues and that high PTPRD expression is positively associated with tumor size, lymph node metastasis, PCNA expression, and patient survival. Moreover, breast cancers with high PTPRD expression tend to exhibit high IL-6 and low phosphorylated-STAT3 expression. IL-6 was found to inhibit miR-34a transcription and induce PTPRD expression in breast cancer and breast epithelial cells, whereas PTPRD was shown to mediate activated STAT3 dephosphorylation and to be a conserved, direct target of miR-34a. IL-6-induced PTPRD upregulation was blocked by miR-34a mimics, whereas experimental PTPRD overexpression suppressed MDA-MB-231 cell migration, invasion, and epithelial to mesenchymal transition, decreased STAT3 phosphorylation, and increased miR-34a transcription. Our findings suggest that PTPRD mediates activated STAT3 dephosphorylation and is induced by the IL-6/STAT3-mediated transcriptional inhibition of miR-34a, thereby establishing a negative feedback loop that inhibits IL-6/STAT3 signaling overactivation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Any materials and data are available from the corresponding author on reasonable request.
Lee EY, Muller WJ (2010) Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol 2:a003236. https://doi.org/10.1101/cshperspect.a003236
Zhu K, Liu Q, Zhou Y, Tao C, Zhao Z, Sun J, Xu H (2015) Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics 16(Suppl 7):S8. https://doi.org/10.1186/1471-2164-16-s7-s8
Wang D, Wang L, Zhou J, Pan J, Qian W, Fu J, Zhang G, Zhu Y, Liu C, Wang C, Jin Z, He Z, Wu J, Shi B (2014) Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma. PLoS ONE 9:e113754. https://doi.org/10.1371/journal.pone.0113754
Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, Pitter KL, Bromberg JF, Huse JT, Holland EC, Chan TA (2014) Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci USA 111:8149–8154. https://doi.org/10.1073/pnas.1401952111
Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J (2010) A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 49:342–352. https://doi.org/10.1002/gcc.20746
Szaumkessel M, Wojciechowska S, Janiszewska J, Zemke N, Byzia E, Kiwerska K, Kostrzewska-Poczekaj M, Ustaszewski A, Jarmuz-Szymczak M, Grenman R, Wierzbicka M, Bartochowska A, Szyfter K, Giefing M (2017) Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma. Tumour Biol 39:1010428317691427. https://doi.org/10.1177/1010428317691427
Lyu J, Song Z, Chen J, Shepard MJ, Song H, Ren G, Li Z, Guo W, Zhuang Z, Shi Y (2018) Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. J Pathol 244:358–366. https://doi.org/10.1002/path.5017
Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Gyorffy B, Dietel M, Loibl S, Weichert W, Stenzinger A (2015) Classical pathology and mutational load of breast cancer—integration of two worlds. J Pathol Clin Res 1:225–238. https://doi.org/10.1002/cjp2.25
Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J (2018) miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut 67:953–962. https://doi.org/10.1136/gutjnl-2016-312270
Hsu HC, Lapke N, Chen SJ, Lu YJ, Jhou RS, Yeh CY, Tsai WS, Hung HY, Hsieh JC, Yang TS, Thiam TK, You JF (2018) PTPRT and PTPRD deleterious mutations and deletion predict bevacizumab resistance in metastatic colorectal cancer patients. Cancers (Basel). https://doi.org/10.3390/cancers10090314
(2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5:e114. https://doi.org/10.1371/journal.pmed.0050114
Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736–746. https://doi.org/10.1038/nrc3818
Wendt MK, Balanis N, Carlin CR, Schiemann WP (2014) STAT3 and epithelial-mesenchymal transitions in carcinomas. Jakstat 3:e28975. https://doi.org/10.4161/jkst.28975
Zhang F, Li L, Yang X, Wang B, Zhao J, Lu S, Yu X (2015) Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats. J Toxicol Pathol 28:79–87. https://doi.org/10.1293/tox.2014-0047
Banerjee K, Resat H (2016) Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 138:2570–2578. https://doi.org/10.1002/ijc.29923
Zhang N, Zhang M, Wang Z, Gao W, Sun ZG (2020) Activated STAT3 could reduce survival in patients with esophageal squamous cell carcinoma by up-regulating VEGF and cyclin D1 expression. J Cancer 11:1859–1868. https://doi.org/10.7150/jca.38798
Chun J, Park MK, Ko H, Lee K, Kim YS (2018) Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways. J Nat Med 72:937–945. https://doi.org/10.1007/s11418-018-1226-6
Zhang S, Yang Y, Huang S, Deng C, Zhou S, Yang J, Cao Y, Xu L, Yuan Y, Yang J, Chen G, Zhou L, Lv Y, Wang L, Zou X (2019) SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling. J Cell Physiol 234:15395–15406. https://doi.org/10.1002/jcp.28186
Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE (2004) Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene 23:168–178. https://doi.org/10.1038/sj.onc.1207003
Tutar L, Ozgur A, Tutar Y (2018) Involvement of miRNAs and Pseudogenes in cancer. Methods Mol Biol 1699:45–66. https://doi.org/10.1007/978-1-4939-7435-1_3
Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H (2014) IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124:1853–1867. https://doi.org/10.1172/jci73531
Li F, Li XJ, Qiao L, Shi F, Liu W, Li Y, Dang YP, Gu WJ, Wang XG, Liu W (2014) miR-98 suppresses melanoma metastasis through a negative feedback loop with its target gene IL-6. Exp Mol Med 46:e116. https://doi.org/10.1038/emm.2014.63
Xiang M, Birkbak NJ, Vafaizadeh V, Walker SR, Yeh JE, Liu S, Kroll Y, Boldin M, Taganov K, Groner B, Richardson AL, Frank DA (2014) STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-kappaB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal 7:ra11. https://doi.org/10.1126/scisignal.2004497
Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y (2017) IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Oncotarget 8:39154–39166. https://doi.org/10.18632/oncotarget.16610
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493–506. https://doi.org/10.1016/j.molcel.2010.07.023
Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC (2009) Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 104:1184–1191. https://doi.org/10.1161/circresaha.109.197491
Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N (2013) Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 32:5272–5282. https://doi.org/10.1038/onc.2012.573
Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ, Shi JS, Lin JD, Chen X (2017) PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res Commun 493:1464–1470. https://doi.org/10.1016/j.bbrc.2017.10.014
Shi X, Kaller M, Rokavec M, Kirchner T, Horst D, Hermeking H (2020) Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer. Cell Mol Gastroenterol Hepatol. https://doi.org/10.1016/j.jcmgh.2020.04.002
Lee HM, Kim TS, Jo EK (2016) MiR-146 and miR-125 in the regulation of innate immunity and inflammation. BMB Rep 49:311–318. https://doi.org/10.5483/bmbrep.2016.49.6.056
Senfter D, Madlener S, Krupitza G, Mader RM (2016) The microRNA-200 family: still much to discover. Biomol Concepts 7:311–319. https://doi.org/10.1515/bmc-2016-0020
Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA (2009) The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 106:9435–9440. https://doi.org/10.1073/pnas.0900571106
Funato K, Yamazumi Y, Oda T, Akiyama T (2011) Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med 2:457–463. https://doi.org/10.3892/etm.2011.231
Pulido R, Serra-Pagès C, Tang M, Streuli M (1995) The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc Natl Acad Sci USA 92:11686–11690. https://doi.org/10.1073/pnas.92.25.11686
Chaudhary F, Lucito R, Tonks NK (2015) Missing-in-metastasis regulates cell motility and invasion via PTPδ-mediated changes in SRC activity. Biochem J 465:89–101. https://doi.org/10.1042/bj20140573
Gonzalez-Quevedo R, Shoffer M, Horng L, Oro AE (2005) Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. J Cell Biol 168:453–463. https://doi.org/10.1083/jcb.200409078
Walia V, Prickett TD, Kim JS, Gartner JJ, Lin JC, Zhou M, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y (2014) Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. Hum Mutat 35:1301–1310. https://doi.org/10.1002/humu.22630
Wu A, Yang X, Zhang B, Wang S, Li G (2019) miR-516a-3p promotes proliferation, migration, and invasion and inhibits apoptosis in lung adenocarcinoma by targeting PTPRD. Int J Clin Exp Pathol 12:4222–4231
Ortiz B, White JR, Wu WH, Chan TA (2014) Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Oncotarget 5:6976–6982. https://doi.org/10.18632/oncotarget.2106
Mohammady M, Ghetmiri SI, Baharizade M, Morowvat MH, Torabi S (2019) Expanding the biotherapeutics realm via miR-34a: "Potent Clever Little" agent in breast cancer therapy. Curr Pharm Biotechnol 20:665–673. https://doi.org/10.2174/1389201020666190617162042
Adams BD, Parsons C, Slack FJ (2016) The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets 20:737–753. https://doi.org/10.1517/14728222.2016.1114102
Li MX, Bi XY, Huang Z, Zhao JJ, Han Y, Li ZY, Zhang YF, Li Y, Chen X, Hu XH, Zhao H, Cai JQ (2015) Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: a systematic review and meta-analysis. PLoS ONE 10:e0127356. https://doi.org/10.1371/journal.pone.0127356
Liu Y, Huang J, Li W, Chen Y, Liu X, Wang J (2018) Meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with breast cancer. Oncotarget 9:13060–13067. https://doi.org/10.18632/oncotarget.23962
Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, Chai Y (2016) Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget 7:19863–19883. https://doi.org/10.18632/oncotarget.7887
This work was supported by the National Natural Science Foundation of China (Grant Number #81272430).
Conflict of interest
The authors declare that they have no conflicts of interest concerning this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Zhang, F., Wang, B., Qin, T. et al. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation. Mol Cell Biochem (2020). https://doi.org/10.1007/s11010-020-03803-w
- Signal transducer and activator of transcription 3
- Protein tyrosine phosphatase receptor type D